인체 혈청에서 추출 정제된 ImmunoglobulinG(IgG)가 임상 병소 분리 녹농균(Ps. aeruginosa) 감염증에 대한 quinolone제제 ciprofloxacin(CPFX)과의 병용 및 단독 투여에 의한 항균효과를 생체감염과 시험관내 실험을 통하여 다음과 같이 요약하였다. 녹농균의 마우스 복강내 감염 후에 마우스 생존율에 의한 항균효과를 IgG 단독 투여군, IgG전 처치후 CPFX 투여군, IgG와 CPFX 동시 투여군 및 CPFX 단독 투여군 순이였다. 녹농균 감염 마우스에서 IgG 단독 투여군에서의 혈액 및 간장내의 생균수는 대조군에 비해 혈액내 균수의 증가는 완만하였으나, 간장내의 균수는 양군 모두 급격한 증가를 나타내었다. PMNL수의 추이는 CPFX 단독 투여군을 제외한 IgG투여군은 감염 후 8시간에 PMNL수가 증가 되었으며, 균 접종 전 IgG투여와 접종 후 IgG투여에 의한 유의적인 차이가 없었다. CPFX의 Ps. aeruginosa에 대한 시험관내 최소 발육 억제 농도는 IgG의 병용 투여에 상관없이 $250{mu}g/ml$의 높은 내성을 나타내었다. 시험관내에서의 IgG의 직접적 항균작용은 인정되지 않았다.
Experiments were performed in mice(Balb/C) to support the basic efficacy of the human immunoglobulin (IgG) preparation. The antibacterial activity of IgG purified from human sera was examined with or without the quinolone agent, ciprofloxacin(CPFX), against Pseudomonas aeruginosa isolated from clinical specimens. Results were as follows: Antibacterial activities in terms of the percentage of survivors, after administration of Ps. aeruginosa into mouse intraperitoneal cavity were in the following order, single IgG group, CPFX administration after IgG pretreatment group, IgG and CPFX combined administration group and CPFX alone group. The number of living bacteria was monitored in blood and liver tissue of mice infected with Ps. aeriginosa and treated by IgG administration. The increase of living bacteria in liver was more drastic than that in blood. Leukocytosis was observed in mice injected with IgG, excluding those only with ciprofloxacin, after 8 hours of administration to see a decrease to normal number of bacteria after 18 hours. No significant difference was noticed between pretreatment group and post treatment group. In vitro susceptibility test of IgG against Ps. aeruginosa, minimal inhibitory concentration(MIC) was $250{mu}g/ml$, resistant to IgG, regardless of a combined administration with CPFX. In vitro test revealed that the IgG itself did not have anti-Ps. aeruginosa activity.
